Raspberry ameliorates renal fibrosis in rats with chronic kidney disease via the PI3K/Akt pathway

被引:0
|
作者
Hu, Jingjing [1 ]
Pang, Xingyuan [1 ]
Liang, Xiao [1 ,2 ]
Shao, Xinyuan [1 ]
Xia, Qijun [1 ]
Sun, Jianwen [1 ]
Wang, Yuxiao [1 ]
Wang, Guichun [1 ]
Li, Shuhan [1 ]
Zha, Liangping [1 ,2 ]
Guo, Jian [1 ,2 ,3 ]
Peng, Chengjun [1 ,2 ,3 ]
Huang, Peng [5 ]
Ding, Yang [1 ,2 ]
Jin, Cheng [1 ,2 ,3 ]
He, Ning [1 ,2 ,3 ]
Huang, Yuzhe [1 ,2 ,3 ]
Gui, Shuangying [1 ,2 ,3 ,4 ,6 ,7 ]
机构
[1] Anhui Univ Chinese Med, Dept Pharm, Hefei 230012, Anhui, Peoples R China
[2] Anhui Acad Chinese Med, Inst Pharmaceut, Hefei 230012, Anhui, Peoples R China
[3] Anhui Prov Key Lab Pharmaceut Preparat Technol & A, Hefei 230012, Anhui, Peoples R China
[4] Anhui Univ Chinese Med, Ctr Xinan Med & Modernizat Tradit Chinese Med IHM, Hefei 230012, Peoples R China
[5] Anhui Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Neurol, Hefei 230031, Anhui, Peoples R China
[6] MOE Anhui Joint Collaborat Innovat Ctr Qual Improv, Hefei 230012, Anhui, Peoples R China
[7] Anhui Engn Res Ctr Qual Improvement & Utilizat Gen, Hefei 230012, Anhui, Peoples R China
关键词
Rubus chingii Hu; Chronic kidney disease; Network pharmacology; PI3K/AKT signaling pathway; DOWN-REGULATION; QUERCETIN; EXTRACT; CELLS; AKT;
D O I
10.1016/j.phymed.2025.156589
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Renal fibrosis is a hallmark of chronic kidney disease (CKD). In traditional Chinese medicine, Rubus chingii Hu (raspberry) is believed to have kidney-tonifying properties. However, whether raspberry can effectively treat CKD, along with the specific active compounds and underlying mechanisms, remains unclear. Purpose: This study aims to investigate the potential of raspberries in treating CKD and elucidate the mechanisms involved. Methods: CKD model was established in rats using adenine. The effects of raspberry treatment on CKD were assessed through macroscopic observations and pathological changes in the kidney. The expression of fibrotic proteins in renal tissues was analyzed to evaluate the impact of raspberry on renal fibrosis. Data mining combined with compositional analysis were employed to identify the active ingredients, targets, and pathways of raspberry that may improve CKD. Subsequently, Western blotting and immunofluorescence analysis were conducted to confirm the involvement of the PI3K/AKT signaling pathway in the renoprotective mechanism of raspberry. Results: Raspberry treatment significantly alleviated renal pathological damage, fibrosis and inflammation in model rats, showing effects comparable to irbesartan (Avapro). Chemical composition analysis and network pharmacology predicted AKT1 as the core target, and the PI3K/AKT pathway plays a pivotal role in mediating the therapeutic effects of raspberry extract in CKD. Molecular docking studies further confirmed that active compounds in raspberry have a strong binding affinity with AKT1. Western blotting and immunofluorescence results demonstrated that raspberry inhibited phosphorylation, thereby suppressing the PI3K/AKT pathway, leading to its antifibrotic effect on the kidney. Conclusion: Raspberry was firstly discovered to potentially treat CKD by alleviating renal fibrosis through inhibition of the PI3K/AKT pathway. Raspberry, as a medicinal and edible traditional herb, could serve as a promising therapeutic agent or health supplement for improving renal fibrosis and slowing CKD progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The role of PI3K/Akt signaling pathway in chronic kidney disease
    Wang, Hongshuang
    Gao, Lanjun
    Zhao, Chenchen
    Fang, Fang
    Liu, Jiazhi
    Wang, Zheng
    Zhong, Yan
    Wang, Xiangting
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (08) : 2623 - 2633
  • [2] Hydrogen sulfide ameliorates doxorubicin-induced myocardial fibrosis in rats via the PI3K/AKT/mTOR pathway
    Nie, Liangui
    Liu, Maojun
    Chen, Jian
    Wu, Qian
    Li, Yaling
    Yi, Jiali
    Zheng, Xia
    Zhang, Jingjing
    Chu, Chun
    Yang, Jun
    MOLECULAR MEDICINE REPORTS, 2021, 23 (04)
  • [3] Aloe-Emodin Ameliorates Renal Fibrosis Via Inhibiting PI3K/Akt/mTOR Signaling Pathway In Vivo and In Vitro
    Dou, Fang
    Liu, YueTong
    Liu, Limin
    Wang, Jingwen
    Sun, Ting
    Mu, Fei
    Guo, Qiyan
    Guo, Chao
    Jia, Na
    Liu, Wenxin
    Ding, Yi
    Wen, Aidong
    REJUVENATION RESEARCH, 2019, 22 (03) : 218 - 229
  • [4] Fasudil suppresses renal fibrosis in diabetic rats through PI3K/AKT signaling pathway
    Han, Zenggang
    Wang, Zhenzhen
    Song, Chunquan
    Sheng, Jianmin
    Niu, Xinqing
    Qi, Pishui
    PANMINERVA MEDICA, 2023, 65 (01) : 119 - 120
  • [5] Tripterygium glycoside ameliorates kidney injury in diabetic rats by regulating the PI3K/Akt signaling pathway
    Hou, Dandan
    Shang, Sainan
    Lv, Juan
    Wang, Shuling
    FOOD SCIENCE AND TECHNOLOGY, 2022, 42
  • [6] Inhibition of Oncogenic Src Ameliorates Silica-Induced Pulmonary Fibrosis via PI3K/AKT Pathway
    Hao, Xiaohui
    Jin, Yixuan
    Zhang, Yiyang
    Li, Shifeng
    Cui, Jie
    He, Hailan
    Guo, Lingli
    Yang, Fang
    Liu, Heliang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [7] Irisin ameliorates D-galactose-induced skeletal muscle fibrosis via the PI3K/Akt pathway
    Wu, Yaoxuan
    Wu, Yongxin
    Yu, Jing
    Zhang, Yingxiao
    Li, Yuanfen
    Fu, Rao
    Sun, Yue
    Zhao, Kexiang
    Xiao, Qian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 939
  • [8] Kokusaginine attenuates renal fibrosis by inhibiting the PI3K/AKT signaling pathway
    Wang, Yuxin
    Han, Yuanyuan
    Shang, Kaiqi
    Xiao, Jing
    Tao, Lijian
    Peng, Zhangzhe
    Liu, Shao
    Jiang, Yueping
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [9] Diosmin ameliorates inflammation, apoptosis and activates PI3K/AKT pathway in Alzheimer's disease rats
    Wang, Yanbo
    Ye, Xiaojun
    Su, Wenwen
    Yan, Ci
    Pan, Haiyan
    Wang, Xiaowei
    Shao, Sen
    METABOLIC BRAIN DISEASE, 2024, 39 (07) : 1405 - 1415
  • [10] Yiqi Qingre Gao alleviates renal fibrosis in UUO mice via PI3K/AKT pathway
    Jin, Qi
    Li, Qian
    Yang, Liping
    Ma, Fang
    Mao, Huimin
    Wang, Yuyang
    Liu, Tongtong
    Peng, Liang
    Li, Ping
    Zhan, Yongli
    FRONTIERS IN PHARMACOLOGY, 2025, 16